EGFR and breast carcinoma: The most widely accepted method in clinical practice is through identification of significant immunohistochemistry (IHC) surrogates for basal-like breast cancer, e.g. epidermal growth factor receptor (EGFR) and basal cytokeratins (CK5/6).